+- +-

+-User

Welcome, Guest.
Please login or register.
 
 
 
Forgot your password?

+-Stats ezBlock

Members
Total Members: 90
Latest: Wallyd
New This Month: 2
New This Week: 1
New Today: 0
Stats
Total Posts: 4718
Total Topics: 2782
Most Online Today: 29
Most Online Ever: 166080
(September 24, 2023, 08:28:44 pm)
Users Online
Members: 0
Guests: 23
Total: 23

Author Topic: Arimidex vs Nolvadex  (Read 115 times)

0 Members and 1 Guest are viewing this topic.

Big Chicken

  • Welcome to the Muscle Science Board
  • Trade Count: (0)
  • Administrator
  • Hero Member
  • *****
  • Posts: 3298
  • Karma: +8/-1
  • You Think I Can't See U
    • View Profile
    • Road2hardCoreIron.net

  • Total Badges: 32
    Badges: (View All)
    2500 Posts Level 6 Fifth year Anniversary
Arimidex vs Nolvadex
« on: July 11, 2021, 04:48:53 am »
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer
F Boccardo et al. J Clin Oncol. 2005.
Show details


Abstract

Purpose: To determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide (150 mg) without compromising efficacy, safety, or sexual functioning.

Patients and methods: A double-blind, placebo-controlled trial was performed in patients with localized, locally advanced, or biochemically recurrent prostate cancer. Patients (N = 114) were randomly assigned to either bicalutamide (150 mg/d) plus placebo or in combination with tamoxifen (20 mg/d) or anastrozole (1 mg/d) for 48 weeks. Gynecomastia, breast pain, prostate-specific antigen (PSA), sexual functioning, and serum levels of hormones were assessed.

Results: Gynecomastia developed in 73% of patients in the bicalutamide group, 10% of patients in the bicalutamide-tamoxifen group, and 51% of patients in the bicalutamide-anastrozole group (P < .001); breast pain developed in 39%, 6%, and 27% of patients, respectively (P = .006). Baseline PSA level decreased by > or = 50% in 97%, 97%, and 83% of patients in the bicalutamide, bicalutamide-tamoxifen, and bicalutamide-anastrozole groups, respectively (P = .07); and adverse events were reported in 37%, 35%, and 69% of patients, respectively (P = .004). There were no major differences among treatments in sexual functioning parameters from baseline to month 6. Elevated testosterone levels occurred in each group; however, free testosterone levels remained unchanged in the bicalutamide-tamoxifen group because of increased sex hormone-binding globulin levels.

Conclusion: Anastrozole did not significantly reduce the incidence of bicalutamide-induced gynecomastia and breast pain. In contrast, tamoxifen was effective, without increasing adverse events, at least in the short-term follow-up. These data support the need for a larger study to determine any effect on mortality.
This board does not condone the use of any medication.  Members should follow City, State, Federal and your countries laws to obtain proper scripts and use of any medication in discussion. We are a private discussion board only.

Share on Facebook Share on Twitter


 

+-Recent Topics

Why Pakistan Bodybuilders are Dying? by Big Chicken
Today at 10:38:07 am

Medical Use of Andriol Capsules by Big Chicken
Today at 10:29:07 am

Steroids or Not Steroids Q & A by Big Chicken
Today at 07:39:43 am

Naturals Do Not Need More Protein by Big Chicken
Today at 07:33:59 am

Pro Bodybuilder Speaks on BBers Bad Habits by Big Chicken
Today at 02:35:52 am

Bostin Loyd's mom. Speaks Out by Big Chicken
March 27, 2024, 01:21:50 pm

ZPHC 30 ML Trenbolone A by Big Chicken
March 27, 2024, 09:13:25 am

ZPHC NEW LINE: 30 ml Vials and 50 Mg Anavar 2024 by Big Chicken
March 27, 2024, 08:25:35 am

Fastest Teenager by Big Chicken
March 27, 2024, 05:37:59 am

Role of Estrogen Blockers by Big Chicken
March 26, 2024, 11:37:03 am